A controlling subsidiary of Livzon Pharmaceutical (HKG:1513, SHE:000513) obtained marketing approval for Leuprorelin Acetate Microspheres for Injection from China's National Medical Products Administration.
The indications of the drug, developed by Shanghai Livzon Pharmaceutical Manufacturing, are premenopausal breast cancer, prostate cancer, and central precocious puberty, a Tuesday Hong Kong bourse filing showed.